On Monday’s trading session, the share price of Mankind Pharma surged by 4.79%, reaching ₹2,012, propelled by the pharmaceutical company’s inclusion in the FTSE All-World, Large-Cap, Total-Cap, and All-Cap indices. Notably, the stock achieved an all-time high at ₹2,032 per share during the intraday session at 11:45 am on November 20.
FTSE, which stands for the Financial Times Stock Exchange Group, is a renowned British company specializing in providing global market index offerings. The FTSE Index is a comprehensive, globally diversified, market-capitalization-weighted benchmark reflecting stock performance across large, mid, and small-cap categories. It encompasses both developed and emerging markets, serving as a foundation for various investment products such as funds, derivatives, and exchange-traded funds.
Mankind Pharma shares opened at ₹1,960.35 on Monday, compared to the previous close at ₹1,920.10 on Friday. The adjustment for Mankind Pharma’s inclusion in the FTSE index is scheduled for December 15.
The significant inclusion of Mankind Pharma in the Large-Cap index underscores the company’s prominent position in the Indian pharmaceutical industry, supported by a substantial market valuation. Other companies, including ACC, Kotak Mahindra Bank, Canara Bank, IDBI Bank, YES Bank, Union Bank of India, Indian Hotels, Jindal Steel & Power, Shriram Finance, Trent, and Tube Investments, are also part of the FTSE index alongside Mankind Pharma.
In the second quarter, Mankind Pharma reported robust performance across various segments, resulting in a 21% increase in consolidated net profit to ₹511 crore. The company’s revenue from operations also demonstrated growth, reaching ₹2,708 crore in the current period compared to ₹2,425 crore in the corresponding period of the previous year.
Disclaimer: The views and investment tips expressed by investment experts on Sharepriceindia.com are their own and not those of the website or its management. Sharepriceindia.com advises users to check with certified experts before taking any investment decisions.
